The Food and Drug Administration (FDA) has approved Zurnai ™, the first nalmefene HCl autoinjector for the emergency treatment of known or suspected opioid overdose in adults an ...

North America & Europe Nalmefene Hydrochloride Market was valued at US$ 4.8 million in 2022 and is projected to surpass the market size of US$ 6.9 million by 2031 at a CAGR of 4.12% during the ...

For the first time, the British Thoracic Society (BTS), National Institute for Health and Care Excellence (NICE) and the Scottish Intercollegiate Guidelines Network (SIGN) have collaborated to develop ...

SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage biotechnology company developing novel therapeutics using its unique AI-driven discovery platform, today announced Enchant™, a ...

Nalmefene hydrochloride injection is an opioid antagonist indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or ...

Naloxone and nalmefene are non-selective tertiary opioid antagonists that are currently available. Neither drug is selective for µ-opioid receptors in the GI tract (both drugs cross the blood ...

is the first nalmefene hydrochloride auto-injector for known or suspected opioid overdose in people aged 12 years and older. Medscape Medical News, August 08, 2024 Alert FDA Approves Vorasidenib ...